Message #8 From:
NewsBot Date: July 27, 2006 05:34:00 AM
BCLI News BrainStorm Cell Therapeutics Retains AGORACOM Investor Relations; AGORACOM to Provide Fully Integrated IR Services Including Access to AOL Small Cap Centre, Yahoo! Finance Canada and 4.3 Million Blackberry Devices
NEW YORK & TEL AVIV, Israel--(BUSINESS WIRE)--July 27, 2006--BrainStorm Cell Therapeutics Inc. (OTCBB:BCLI), the developer of NurOwn(TM) bone marrow-derived-stem cell therapeutic products for the treatment of neurodegenerative diseases, announced today that the company has retained the services of AGORACOM Investor Relations Corp. (http://www.agoracom.com) to provide investor relations services.
AGORACOM is the exclusive provider of all content to the AOL Small Cap Centre, as well as, a small-cap content provider to Yahoo! Finance Canada and all 4.3 million Blackberry devices around the world. The objective of this agreement is two-fold: first, to create effective communication among BrainStorm, its shareholders, and the investment community through AGORACOM's Internet-based investor relations system. Effective immediately, a customized and monitored BrainStorm IR HUB (www.agoracom.com/IR/BrainStorm) will allow both BrainStorm and AGORACOM to communicate with all investors simultaneously, anytime, while providing shareholders with equal access and complete transparency to all investor relations communications. The IR HUB will also provide one-click access to the BrainStorm broker fact sheet, company profile, five most recent press releases, e-mail list registration, latest stock quote and chart information, and an executive audio address updated quarterly. In addition, the IR HUB provides investors with a monitored discussion forum for the purposes of constructive and high-quality discussion about the Company that is free of spam, bashing, hyping and profanity. Second, AGORACOM will be fully responsible for creating, implementing and executing an investor relations strategy. This consolidation will save management a considerable amount of time, effort and expense, allowing them to focus on core business operations, while significantly improving shareholder communications.
BrainStorm's COO & principal executive officer Yoram Drucker, stated, "We believe the time has now come to significantly increase our communications with shareholders and the investment community. The solution provided by AGORACOM fulfills our need to manage and execute an IR strategy in a cost efficient manner, while providing our management team with the ability to focus on executing the business plan. Our shareholders and the company will benefit greatly from near real-time communications, regularly planned updates and increased exposure."
For all future BrainStorm investor relations needs, investors are asked to visit the BrainStorm IR Hub at http://www.agoracom.com/IR/BrainStorm where they can post questions and receive answers within the same day, or simply review questions and answers posted by other investors. Alternatively, investors are able to e-mail all questions and correspondence to BCLI@agoracom.com where they can also request their addition to the investor e-mail list to receive all future press releases and updates in real time.
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is an emerging company developing neural-like stem cell therapeutic products, NurOwn(TM), based on autologous bone marrow-derived stromal cells, for treatment of neurodegenerative diseases. NurOwn(TM) patent pending technology is based on discoveries made by the team led by prominent neurologist Professor Eldad Melamed, Head of Neurology at Rabin Medical Center, and expert cell biologist Dr. Daniel Offen, Head of the Neuroscience Laboratory at the Felsenstein Medical Research Center of Tel-Aviv University, enabling the differentiation of bone marrow derived stem cells into functional neurons and astrocytes, as demonstrated in animal models. The Company holds rights to develop and commercialize the technology through an exclusive, worldwide licensing agreement with Ramot at Tel Aviv University Ltd., the technology transfer company of Tel-Aviv University. The company's initial focus is on developing treatments for Parkinson's disease.
About Stem Cell Therapy
Stem cells are non-specialized cells with a remarkable potential for both self-renewal and differentiation into cell types with a specialized function, such as muscle, blood or brain cells. Stem cells can be harvested from fetal or embryonic tissue or from adult tissue reservoirs such as bone marrow. Use of embryonic stem cells is at the center of significant ethical and moral debate. In contrast, use of adult stem cells does not provoke the same moral or political controversy. Stem cell therapy aims to "cure" disease by replacing the diseased cells with healthy cells derived from stem cells. This approach has the potential to revolutionize medicine and, if successful, the implied commercial opportunities are great. Currently, scientists are exploring both embryonic stem cells (ESC) and adult stem cells (ASC) as the potential basis for multiple cell therapy products.
AGORACOM Investor Relations Corp. (AGORACOM) is North America's leading outsourced investor relations firm for small-cap companies. AGORACOM's exclusive IR HUB delivers two-way investor relations and communications that provides 100% transparency, accessibility, equality and near real-time communications for all shareholders and the investment community. The digital delivery of investor relations also provides public companies with savings over traditional services ranging from 50-60%. AGORACOM is a private company and has specialized in small-cap investor relations since 1997. AGORACOM is located in Toronto, Ontario.
Safe Harbor Statement
Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. The potential risks and uncertainties include, among others, risks associated with BrainStorm Cell Therapeutics Inc.'s limited operating history, history of losses and expectation to incur losses for the foreseeable future; limited cash resources and its need to raise additional capital to execute on its business plan and continue operations; transition issues related to the departure of its CEO; dependence on its license to Ramot's technology and ability to meet its funding and payment obligations included in such license agreement; ability, together with its licensor, to adequately protect the NurOwn(TM) technology; dependence on key executives and on its scientific consultants; ability to identify, negotiate and successfully implement strategic partnering relationships; ability to complete clinical trials successfully and to obtain required regulatory approvals; competition with companies, some of which have greater resources and experience in developing and obtaining regulatory approval for treatments in BrainStorm Cell Therapeutics Inc.'s market; the limited public trading market for BrainStorm Cell Therapeutics Inc.'s stock which may never develop into an active market; and other factors detailed in BrainStorm Cell Therapeutics Inc.'s annual report on Form 10-KSB, quarterly reports on Form 10-QSB, current reports on Form 8-K and other filings with the Securities and Exchange Commission available at http://www.sec.gov/ or by request to the Company. The Company does not undertake any obligation to update forward-looking statements made by us.
